Buprenorphine is a schedule III opioid medication and a partial opioid agonist. It is an evidence based medication for opioid use disorder that mitigates risk of nonfatal and fatal overdose because of it's ceiling effect on respiratory depression. The most common formulations are sublingual as the monoproduct (i.e. Subutex) or in combination with naloxone (ie. Suboxone).